These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27790483)

  • 1. Effect of Poly Unsaturated Fatty Acids Administration on Children with Attention Deficit Hyperactivity Disorder: A Randomized Controlled Trial.
    Anand P; Sachdeva A
    J Clin Diagn Res; 2016 Sep; 10(9):OC01-OC05. PubMed ID: 27790483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children].
    Escobar R; Hervas A; Soutullo C; Mardomingo MJ; Uruñuela A; Gilaberte I
    Actas Esp Psiquiatr; 2008; 36(5):285-94. PubMed ID: 18830848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
    Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
    Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls.
    Parletta N; Niyonsenga T; Duff J
    PLoS One; 2016; 11(5):e0156432. PubMed ID: 27232999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind placebo-controlled randomised trial of omega-3 supplementation in children with moderate ADHD symptoms.
    Cornu C; Mercier C; Ginhoux T; Masson S; Mouchet J; Nony P; Kassai B; Laudy V; Berquin P; Franc N; Le Heuzey MF; Desombre H; Revol O
    Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):377-384. PubMed ID: 28993963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study.
    Bélanger SA; Vanasse M; Spahis S; Sylvestre MP; Lippé S; L'heureux F; Ghadirian P; Vanasse CM; Levy E
    Paediatr Child Health; 2009 Feb; 14(2):89-98. PubMed ID: 19436468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials.
    Puri BK; Martins JG
    Prostaglandins Leukot Essent Fatty Acids; 2014 May; 90(5):179-89. PubMed ID: 24560325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia in a Randomized, Placebo-Controlled Trial.
    Shaywitz S; Shaywitz B; Wietecha L; Wigal S; McBurnett K; Williams D; Kronenberger WG; Hooper SR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):19-28. PubMed ID: 27410907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Crippa A; Tesei A; Sangiorgio F; Salandi A; Trabattoni S; Grazioli S; Agostoni C; Molteni M; Nobile M
    Eur Child Adolesc Psychiatry; 2019 Apr; 28(4):571-583. PubMed ID: 30246216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
    Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
    J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
    Rodríguez C; García T; Areces D; Fernández E; García-Noriega M; Domingo JC
    Neuropsychiatr Dis Treat; 2019; 15():1193-1209. PubMed ID: 31190827
    [No Abstract]   [Full Text] [Related]  

  • 19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
    Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
    Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.